» Articles » PMID: 36983804

Does an Association Among Sarcopenia and Metabolic Risk Factors Exist in People Older Than 65 Years? A Systematic Review and Meta-Analysis of Observational Studies

Abstract

Sarcopenia is defined as the generalized and progressive loss of skeletal muscle strength and mass that may be affected by metabolic factors, although this relationship has been poorly studied. The aim of this review and meta-analysis was to analyze the relationship among the different metabolic risk factors and sarcopenia in people older than 65 years. Following the PRISMA 2020 guide, we searched for articles that studied the relationship among sarcopenia and metabolic risk factors in adults over 65 years of age, published between 2012 and 2022 in four databases: PubMed, Web of Science, Cochrane Plus, and CINAHL. A total of 370 articles were identified in the initial search, of which 13 articles were selected for inclusion in this review. It was observed that metabolic risk factors such as Body Mass Index, systolic and diastolic blood pressure, glucose, cholesterol, or triglycerides had a significant association with sarcopenia. There is evidence of the association of different metabolic risk factors with sarcopenia in adults over 65 years of age, so it is necessary to carry out studies that investigate different strategies that reduce the appearance of sarcopenia, and with it, the incidence of metabolic diseases.

Citing Articles

Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets.

Ali S, Nkembo A, Tipparaju S, Ashraf M, Xuan W Can J Physiol Pharmacol. 2024; 102(12):697-708.

PMID: 39186818 PMC: 11663012. DOI: 10.1139/cjpp-2024-0201.


Sarcopenia and aortic valve disease.

Kumar M, Pettinato A, Ladha F, Earp J, Jain V, Patil S Heart. 2024; 110(15):974-979.

PMID: 38649264 PMC: 11236523. DOI: 10.1136/heartjnl-2024-324029.


Relationships of Fat Mass Index and Fat-Free Mass Index with Low-Density Lipoprotein Cholesterol Levels in the Tohoku Medical Megabank Community-Based Cohort Study.

Takase M, Nakamura T, Nakaya N, Kogure M, Hatanaka R, Nakaya K J Atheroscler Thromb. 2024; 31(6):979-1003.

PMID: 38325860 PMC: 11150719. DOI: 10.5551/jat.64535.


Bezafibrate attenuates immobilization-induced muscle atrophy in mice.

Nakamura S, Sato Y, Kobayashi T, Oya A, Fujie A, Matsumoto M Sci Rep. 2024; 14(1):2240.

PMID: 38279013 PMC: 10817916. DOI: 10.1038/s41598-024-52689-x.

References
1.
Steffl M, Bohannon R, Sontakova L, Tufano J, Shiells K, Holmerova I . Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis. Clin Interv Aging. 2017; 12:835-845. PMC: 5441519. DOI: 10.2147/CIA.S132940. View

2.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

3.
Rejnmark L . Effects of vitamin d on muscle function and performance: a review of evidence from randomized controlled trials. Ther Adv Chronic Dis. 2012; 2(1):25-37. PMC: 3513873. DOI: 10.1177/2040622310381934. View

4.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

5.
Ma L, Wang Y, Yang Z, Huang D, Weng H, Zeng X . Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?. Mil Med Res. 2020; 7(1):7. PMC: 7049186. DOI: 10.1186/s40779-020-00238-8. View